Log In
Print
BCIQ
Print
Print this Print this
 

Addyi, flibanserin (formerly BIMT-17)

  Manage Alerts
Collapse Summary General Information
Company Sprout Pharmaceuticals Inc.
DescriptionSerotonin (5-HT1A) receptor agonist and 5-HT2A receptor antagonist
Molecular Target Serotonin (5-HT1A) receptor ; Serotonin (5-HT2A) receptor
Mechanism of ActionSerotonin (5-HT1A) receptor agonist; Serotonin (5-HT2A) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationSexual dysfunction
Indication DetailsTreat hypoactive sexual desire disorder (HSDD) in premenopausal women
Regulatory Designation U.S. - Undisclosed Review (Treat hypoactive sexual desire disorder (HSDD) in premenopausal women)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,000.0M

$1,000.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today